Screener
ImmunityBio, Inc. IBRX Cash Flow Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| -$230.39M-149% | -$632.8M-388% | -$61.96M-4.7% | -$67.27M+21.5% | -$92.57M+31.2% | ||
| $4.41M+13.6% | $4.38M+14.4% | $3.87M-6.6% | $3.95M-11.3% | $3.88M-11.9% | ||
| $8.52M-11.7% | $8.17M-14.3% | $8.75M-3.2% | $8.88M+18.5% | $9.65M+0.1% | ||
| -$66.49M+16.6% | -$75.36M+12.3% | -$70.38M+17.3% | -$68.91M+30.2% | -$79.75M+20.5% | ||
| $3.52M+225% | $1.78M+58.4% | $903K-57.2% | $741K-73.5% | $1.08M+49.3% | ||
| -$107.47M-566% | -$31.65M-867% | —— | -$181.36M— | -$16.14M+68.7% | ||
| —— | $61K— | —— | —— | $0— | ||
| $886K— | $868K— | —— | —— | $0— | ||
| $44.44M-74.3% | $223.93M+22,903% | $54.89M-48.7% | $173.52M+1,014% | $172.81M+16.1% | ||
| -$129.52M— | $117.04M+241% | —— | -$76.81M-323% | —— | ||
| -$70.01M+13.4% | -$77.14M+11.4% | -$71.28M+18.3% | -$69.65M+31.4% | -$80.83M+20.0% |
FAQ
- How much cash does ImmunityBio, Inc. generate?
- ImmunityBio, Inc. (IBRX) generated -$281.1M in operating cash flow over the trailing twelve months.
- What is ImmunityBio, Inc.'s free cash flow?
- After $6.9M of capital expenditures, ImmunityBio, Inc.'s free cash flow was -$288.1M over the trailing twelve months, up 19.2% year over year.
- Where does ImmunityBio, Inc.'s cash flow data come from?
- Every line is extracted from ImmunityBio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
